Fabry disease is a genetic disorder caused by the GLA defective gene, due to which specific fatty matters start accumulating in multiple tissues of the body. Fabry disease reduces life expectancy by approximately 15-20 years. According to the U.S. National Library of Medicine, it is estimated that 1 in 40,000 to 60,000 males get affected by this disease, which is rarely found in females. This disease is also known by various names such as GLA deficiency, Anderson-Fabry disease, angiokeratoma diffuse, alpha-galactosidase A deficiency, and hereditary dystopic lipidosis.

The Fabry disease treatment market is driven by various factors such as the development of novel therapies for the treatment of the disease, extensive approval of pipeline products, also the demand for messenger RNA as a treatment modality for Fabry disease.

Moreover, a rising patient base and the support provided by the government regulatory authorities, such as the Food and Drug Administration (FDA), for the treatment of Fabry diseases are expected to propel the growth of the Fabry disease treatment market.

However, lack of awareness about advanced treatment therapies and lower adoption of newly developed technology and novel therapies due to less investments by governments are expected to slow down the growth of the market. Further, the side effects associated with treatment are also anticipated to hamper the growth of the Fabry disease treatment market.

Segmentation

The Fabry disease treatment market segmentation is based on treatment and region.

Treatment Outlook

Based on treatment, the market is segmented into Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), and Chaperone Treatment. The enzyme replacement therapy segment is anticipated to dominate the market. Strong sales of Fabrazyme and Replagal and the potential of promising pipeline candidates getting approval are driving the growth of this segment and helping the segment to maintain its dominance.

Regional Outlook

Based on regions, the Fabry treatment market is categorized into North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, & Rest of the World. North America is anticipated to dominate the market owing to extensive research and development activities for the development of novel therapies, favorable reimbursement policies, and the presence of developed healthcare facilities in the region.

The Asia Pacific region is expected to grow in the coming years, as this region has immense growth opportunities for the pharmaceutical industry due to rising investments by governments in the healthcare sector. This is expected to boost the Fabry disease treatment market in the Asia Pacific region.

Market Players

The key leading players in Fabry Disease Treatment market include JCR Pharmaceuticals Co Ltd, Amicus Therapeutics Inc, Avrobio Inc, Sanofi S.A, Protalix Biotherapeutics Inc., Shire Plc., Moderna Therapeutics Inc, Avrobio Inc, and Takeda Pharmaceutical Co. Ltd.

Key Development

May 2018 - Amicus Therapeutics initiated the commercial launch of the oral small molecule pharmacological chaperone Galafold capsules 123mg (migalastat) for the treatment of patients aged 16 years and older with a confirmed diagnosis of Fabry disease (alpha-galactosidase A deficiency).

August 2018 - Amicus Therapeutics announced the U.S. Food and Drug Administration’s (FDA) approval of Galafold (migalastat) 123 mg capsules, which is used for the treatment of Fabry disease.

May 2020 - AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, has announced new clinical data from its investigational programs for Fabry disease and cystinosis.

What Does This Report Provide?

This report provides a detailed understanding of the global Fabry disease treatment market from qualitative and quantitative perspectives during the forecast period. The report also provides dynamic indicators with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.

Market Segmentation:

By Treatment

• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Therapy (SRT)
• Chaperone Treatment

By Region:

• North America Fabry Disease Treatment Market
  • By Country (US, Canada, Mexico)
  • By Treatment
• Western Europe Fabry Disease Treatment Market
  • By Country (Germany, Russia, UK, France, Italy, Spain, Rest of Western Europe)
  • By Treatment
• Asia Pacific Fabry Disease Treatment Market
  • By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
  • By Treatment
• Middle East & Africa Fabry Disease Treatment Market
  • By Country (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa)
  • By Treatment
• South America Fabry Disease Treatment Market
  • By Country (Brazil, Argentina, Colombia, Rest of South America)
  • By Treatment

Reasons to Buy This Report:

• Market size estimation of the Fabry disease treatment market on a regional and global basis
• Unique research usage for market size estimation and forecast
• Profiling of major companies operating in the market with key developments
• Broad scope to cover all the possible segments helping every stakeholder in the market

Customization:

We provide customization of the study to meet specific requirements:

• By Segment
• By Sub-segment
• By Region/Country

For more information, contact: [email protected]